New White Paper: Meeting the challenge of synthesizing complex therapeutic peptides
The demand for increasingly complex therapeutic peptides has resulted in the development of robust, efficient, and rapid synthesis protocols and instrumentation that can meet the demands of GxP and regulatory authorities. Read more about synthesizing complex therapeutic peptides.
Complexity can have many forms:
- Longer peptides, for example >30 amino acids, in itself is a challenge to synthesize, for example when synthesizing chemokines or histones.
- Highly hydrophobic peptides such as beta-amyloids involved in Alzheimer’s disease and extensively used in research.
- Cyclic peptides, in efforts to improve the rigidity, stability and resistance to degradation of therapeutic peptides. These are stapled, disulfide-bridged, bicyclic, or cyclized head-to-tail. Cyclotides, for example, are stable to proteolytic attack and have high thermal stability due to their highly constrained structure created by a head-to-tail cyclic backbone and three disulfide bonds that form a cystine-knotted core.